Cerebrolysin
PeptideCerebrolysin is a neuropeptide preparation derived from porcine brain tissue, consisting of low-molecular-weight peptides and free amino acids that mimic the action of endogenous neurotrophic factors. It is approved in over 50 countries (though not in the USA) for the treatment of stroke, traumatic brain injury, and dementia. Multiple randomized controlled trials and meta-analyses have evaluated its efficacy, showing consistent improvements in early neurological recovery after ischemic stroke and modest cognitive benefits in Alzheimer's disease, with a safety profile comparable to placebo.
Quick Answer
What it is
Cerebrolysin is a neuropeptide preparation derived from porcine brain tissue, consisting of low-molecular-weight peptides and free amino acids that mimic the action of endogenous neurotrophic factors. It is approved in over 50 countries (though not in the USA) for the treatment of stroke, traumatic brain injury, and dementia.
Key findings
- Grade B: Neuroprotection
- Grade B: Stroke Recovery (Early Neurological Function) (Neurological Health)
- Grade B: Traumatic Brain Injury Recovery (Neurological Health)
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
⚠️ Research Notice
This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.
ℹ️ Quick Facts: Cerebrolysin
Quick Facts: Cerebrolysin
- Best Evidence:Grade B
- Conditions Studied:2
- Research Outcomes:19
- Grade B Findings:6
- Key Effect:Neurological Health
Detailed Outcomes
Evidence by Condition
Research Citations (49)
Related Peptides
Semax
Peptide1 shared condition · 14 outcomes
Semax is a synthetic heptapeptide derived from ACTH (adrenocorticotropic hormone). It has been approved as a prescription medication in Russia and Ukraine for treating stroke, cognitive disorders, and peptic ulcers. Research suggests it may enhance BDNF expression and exhibit nootropic and neuroprotective effects. Most clinical research has been conducted in Russia, with limited Western clinical trials.
Pinealon
Peptide1 shared condition · 4 outcomes
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by Russian researchers as part of the Khavinson peptide bioregulators. It is designed to target brain tissue and has been studied for potential neuroprotective and cognitive-enhancing effects. Research suggests it may help regulate circadian rhythms and support cognitive function in aging, though human clinical data is limited.
Humanin
Peptide1 shared condition · 23 outcomes
Humanin (HN) is a 24-amino-acid mitochondrial-derived peptide encoded within the 16S rRNA gene of mitochondrial DNA. Discovered in 2001 from preserved brain tissue of Alzheimer's patients, it demonstrates potent neuroprotective, cytoprotective, and metabolic regulatory effects. Humanin levels decline with age but remain stable in long-lived species and are elevated in offspring of centenarians.
GHRP-6
Peptide1 shared condition · 13 outcomes
GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide (His-DTrp-Ala-Trp-DPhe-Lys-NH2) that potently stimulates growth hormone secretion. Developed in the 1980s by Cyril Bowers, it was the first synthetic peptide shown to specifically elicit dose-dependent GH release both in vitro and in vivo. GHRP-6 acts through the ghrelin receptor (GHS-R1a) and CD36 receptor, exhibiting not only GH-releasing properties but also significant cytoprotective, cardioprotective, and wound healing effects. It increases IGF-1 levels, stimulates appetite, and has demonstrated tissue-protective properties in multiple preclinical and clinical studies. While primarily researched for GH deficiency, emerging evidence supports its potential in wound healing, scar prevention, and cardioprotection.